The Cooper Companies Inc COO

Stock XNAS Rating as of Jun 5, 2026

$66.79 −0.55 (0.82%)

View Full Chart

As of Jun 8, 2026, 8:00:11 PM Delayed Price Closed

Company Report

View Archive

Cooper Earnings: Asia Remains Weak, but All Wheels Elsewhere Are Turning in the Right Direction

Keonhee Kim Jun 5, 2026

CooperCompanies delivered 8% (5% organic) and 26% revenue and adjusted EPS growth, respectively, during the second fiscal quarter. Both figures landed ahead of FactSet consensus. Shares are trading sideways after hours.

Read Full Report

Price vs Fair Value

View History

COO is trading at a 217% premium.

Price

$67.34

Jun 5, 2026

Fair Value

$64.00

Dec 5, 2025

Uncertainty

Medium

1-Star Price: $585.37
5-Star Price: $17.90
Economic Moat: Pklrhf
Capital Allocation: Sbtwnqql

Bulls Say, Bears Say

Bulls

Cooper is one of the leading visioncare companies in the world with a proven record of successful product development. Recent innovations like MiSight widen Cooper's end market and fuel the firm's future growth trajectory.

Bears

While the contact lens market share has been stable, lagging research and innovation could start to chip away at Cooper's presence in the space.

Trading Information

Previous Close Price: $67.34
Day Range: $65.59–68.18
52-Week Range: $58.89–89.83
Bid/Ask: $65.55 / $66.76
Shares Outstanding: 195.03M
Market Cap: $13.03B
Volume/Avg: 7M / 2M

Key Statistics

Price/Earnings (Normalized): 14.65
Price/Sales: 3.12
Dividend Yield (Trailing): 0.00%
Dividend Yield (Forward): 0.00%
Total Yield: 2.74%

Company Profile

CooperCompanies is one of the largest eyecare companies in the US. It operates in two segments: CooperVision and CooperSurgical. CooperVision is a pure-play contact lens business with a suite of spherical, multifocal, and toric contact lenses. The company also has one of the most comprehensive specialty lens portfolios in the world. With brands including Proclear, Biofinity, MyDay, and Clariti, Cooper controls roughly one fourth of the US contact lens market. CooperSurgical, founded in 1990, is made up of equipment related to reproductive care, fertility, and women’s care. Cooper has the broadest medical device coverage of the entire IVF cycle. It also has Paragard, the only hormone-free IUD in the US, and controls 17% of the US IUD market.

Sector: Healthcare
Industry: Medical Instruments & Supplies
Stock Style Box: Small Core
Total Number of Employees: 15,000
Website: https://www.coopercos.com

Competitors

Johnson & Johnson

JNJ

Valuation

Metric	COO	JNJ
Price/Earnings (Normalized)	14.65	21.64
Price/Book Value	1.58	6.88
Price/Sales	3.12	5.87
Price/Cash Flow	14.02	18.97

Price/Earnings

COO

JNJ

Financial Strength

Metric	COO	JNJ
Quick Ratio	0.53	0.77
Current Ratio	1.27	1.03
Interest Coverage	5.43	24.09

Quick Ratio

COO

JNJ

Profitability

Metric	COO	JNJ
Return on Assets (Normalized)	1.90%	13.33%
Return on Equity (Normalized)	2.84%	32.77%
Return on Invested Capital (Normalized)	2.86%	20.14%

Return on Assets

COO

JNJ

Medical Instruments & Supplies Industry Comparables

Screen With Investor

Name	Capital Allocation	Economic Moat	Market Cap
Intuitive Surgical Inc ISRG	Gfjcrgnx	Bfph	$149B
Becton Dickinson & Co BDX	Twsfp	Zmpbyh	$42B
Alcon Inc ALC	Hcqpzplh	Mnbdzk	$33B
ResMed Inc RMD	Mkqxcxnjr	Kmpmrd	$28B
Medline Inc Ordinary Shares - Class A MDLN	Nkslgtnz	Zmcljf	$28B
West Pharmaceutical Services Inc WST	Gmkkymjnd	Gmgf	$22B
Solventum Corp SOLV	Dyjynzs	Lsb	$14B
Align Technology Inc ALGN	Xqlnhvg	Rvhwhjz	$12B
Baxter International Inc BAX	Hzsq	Slktfj	$10B